Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.
Robert LeCates, MA
Advertisement
Articles by Robert LeCates, MA
Advertisement
Latest Updated Articles
- Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients
Published: December 13th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Improving Access and Care for All Patients With Atopic Dermatitis
5
